Emergency vaccine revenues aren’t forever, but they’re sweet while they last. Now, Bavarian Nordic—on a global supply pact tear with its monkeypox shot Jynneos—has locked in a deal with Canada that could keep sales rolling for years.
Canada’s public health agency has amended an earlier contract from June, laying out $234 million more for an undisclosed number of Jynneos doses, which bear the name Imvamune in Canada.
The vaccine accord includes another $180 million in options for Canada to acquire even more doses of BN’s smallpox/monkeypox shot each year through 2032.
Including an earlier $56 million supply contract from June, BN has secured a total supply deal worth up to $470 million in the Great White North.
The vaccine specialist says it'll deliver the majority of Canada’s vaccine order in 2023. Canada can continue to buy additional doses each year after that for the next 10 years.
Still, the exact number of Imvamune doses bound for Canada remains unclear.
The monkeypox case count in Canada currently sits at around 1,363, according to the Centers for Disease Control and Prevention (CDC).
In the U.S., the CDC has reported more than 24,000 monkeypox cases.
Stateside, BN has agreed to supply roughly 7 million doses of its shot since 2020.